Back to Agenda
New Resource from the DIA Interdisciplinary Disclosure Working Group
Session Chair(s)
Eileen Girten, MS
Director, Medical Writing
Pfizer Inc, United States
Seating is limited
Clinical trial transparency requirements and initiatives have been changing the clinical trial disclosure landscape and affecting multiple functions within the pharmaceutical industry. Individuals within the pharmaceutical industry have held ongoing discussions identifying what is in scope for these requirements and finding ways to meet these regulatory requirements. Because these transparency regulations affect multiple stakeholders, a need for a group of professionals across functions to develop resources was needed. This session will highlight a resource developed by the DIA Interdisciplinary Disclosure Working Group for implementing clinical trial disclosures in the biopharma industry. This session will discuss the creation of this resource and how it may be used by professionals involved in clinical trial disclosure.
(Submitted on behalf of the DIA Interdisciplinary Disclosure Working Group
Learning Objective : Identify the challenges and opportunities in clinical trial transparency and disclosure; Discuss what skills and knowledge may be useful for those individuals involved in transparency and disclosure; Describe how the Interdisciplinary Working Group resource may be used by clinical trial disclosure stakeholders.
Have an account?